NOVEMBER 2013

29 November 2013 – Data from Final Cohort of Patients in Multiple Myeloma Clinical Trial
19 November 2013 – Patrys Presents at BBY Life Sciences Conference
18 November 2013 – Patrys Granted Australian Patent for PAT-SM6
13 November 2013 – Patrys Announces $12.5M Rights Issue
11 November 2013 – Patrys to Initiate Clinical Trial with Onyx Pharmaceuticals
8 November 2013 – Patrys Granted US Patent for Lead Product PAT-LM1
6 November 2013 – USA FDA Grants Orphan Drug Status for PAT-SM6

OCTOBER 2013

23 October 2013 – CEO Presentation to AGM
18 October 2013 – Retirement of Director – Dr. Alan Robertson
14 October 2013 – Patrys Ltd – Open Briefing
10 October 2013 – Patrys to Present at ASH International Conference
9 October 2013 – Patrys CEO Presents at BIO Investor Forum

SEPTEMBER 2013

13 August 2013 – PAT-SM6 Receives Orphan Drug Designation for Multiple Myeloma in Europe

AUGUST 2013

13 August 2013 – Data from 2nd and 3rd Cohorts in Multiple Myeloma Trial
 7 August 2013 – Patrys’ Multiple Myeloma Clinical Trial to Progress to Final Patient Group

JULY 2013

24 July 2013 – Treatment of 3rd Patient Group in MM Trial Completed
10 July 2013 – ARC Linkage Grant to Support PAT-SM6 Diagnostics Development

JUNE 2013

11 June 2013 – Further Data on the Effectiveness of PAT-SM6 Published
  6 June 2013 – Patrys Granted Key Patent for Lead Product PAT-LM1

MAY 2013

8 May 2013 – PAT-SM6 Kills Human Multiple Myeloma Cells
6 May 2013 – Patrys Hosts 2nd IgM Conference

APRIL 2013

23 April 2013 – Patrys Progresses Multiple Myeloma Clinical Trial to Third Patient Group
22 April 2013 – New Data Strengthens PAT-SM6 Profile as an Anti-cancer Treatment
13 April 2013 – Treatment of Second Patient Group in MM Trial Completed

MARCH 2013

20 March 2013 – Preclinical Results Support PAT- SM6 Multiple Myeloma Programme
  7 March 2013 – Data from 1st Cohort in Multiple Myeloma Trial

JANUARY 2013

14 January 2013 – Patrys Progresses Multiple Myeloma Trial to Second Group